| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
|
Blood
|
2011
|
7.49
|
|
2
|
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
|
Lancet Oncol
|
2009
|
5.45
|
|
3
|
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
|
Clin Cancer Res
|
2007
|
5.36
|
|
4
|
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.
|
J Natl Cancer Inst
|
2009
|
5.05
|
|
5
|
Altered bone and mineral metabolism in patients receiving imatinib mesylate.
|
N Engl J Med
|
2006
|
4.71
|
|
6
|
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
|
Clin Cancer Res
|
2002
|
3.72
|
|
7
|
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
|
Blood
|
2005
|
3.65
|
|
8
|
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.
|
Clin Cancer Res
|
2007
|
3.53
|
|
9
|
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.
|
Nat Med
|
2007
|
3.07
|
|
10
|
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.
|
J Clin Invest
|
2012
|
3.00
|
|
11
|
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.
|
Blood
|
2010
|
2.73
|
|
12
|
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
|
J Clin Oncol
|
2008
|
2.68
|
|
13
|
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
|
Blood
|
2011
|
2.68
|
|
14
|
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
|
Clin Cancer Res
|
2007
|
2.50
|
|
15
|
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
|
J Clin Oncol
|
2011
|
2.45
|
|
16
|
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
|
Clin Cancer Res
|
2005
|
2.44
|
|
17
|
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
|
J Clin Oncol
|
2012
|
2.26
|
|
18
|
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
|
Eur Urol
|
2011
|
2.14
|
|
19
|
Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.
|
J Immunol
|
2007
|
2.12
|
|
20
|
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.
|
J Clin Invest
|
2005
|
2.10
|
|
21
|
IL-17 contributes to CD4-mediated graft-versus-host disease.
|
Blood
|
2008
|
2.07
|
|
22
|
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
|
J Clin Oncol
|
2004
|
2.04
|
|
23
|
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.
|
Nat Clin Pract Oncol
|
2006
|
1.99
|
|
24
|
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.
|
Clin Cancer Res
|
2005
|
1.97
|
|
25
|
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.
|
J Clin Oncol
|
2011
|
1.94
|
|
26
|
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes.
|
Nat Biotechnol
|
2003
|
1.87
|
|
27
|
Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities.
|
Biol Blood Marrow Transplant
|
2010
|
1.83
|
|
28
|
The association between measures of progression and survival in castrate-metastatic prostate cancer.
|
Clin Cancer Res
|
2007
|
1.83
|
|
29
|
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
|
Clin Cancer Res
|
2007
|
1.80
|
|
30
|
Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells.
|
J Immunol
|
2004
|
1.77
|
|
31
|
A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions.
|
Biol Blood Marrow Transplant
|
2009
|
1.76
|
|
32
|
Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor.
|
J Clin Endocrinol Metab
|
2006
|
1.74
|
|
33
|
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
|
J Clin Oncol
|
2008
|
1.71
|
|
34
|
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.
|
Clin Cancer Res
|
2009
|
1.68
|
|
35
|
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease.
|
Blood
|
2003
|
1.67
|
|
36
|
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.
|
Clin Cancer Res
|
2005
|
1.64
|
|
37
|
A competing-risks nomogram for sarcoma-specific death following local recurrence.
|
Stat Med
|
2003
|
1.57
|
|
38
|
Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations.
|
Blood
|
2002
|
1.53
|
|
39
|
Quantifying the amount of variation in survival explained by prostate-specific antigen.
|
Clin Cancer Res
|
2002
|
1.52
|
|
40
|
Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.
|
Blood
|
2005
|
1.51
|
|
41
|
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.50
|
|
42
|
Second-line chemotherapy for prostate cancer: patient characteristics and survival.
|
Clin Prostate Cancer
|
2005
|
1.49
|
|
43
|
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.
|
Cancer Res
|
2011
|
1.48
|
|
44
|
CCR2 is required for CD8-induced graft-versus-host disease.
|
Blood
|
2005
|
1.43
|
|
45
|
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2012
|
1.42
|
|
46
|
An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment.
|
Blood
|
2010
|
1.41
|
|
47
|
Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma.
|
Pediatr Blood Cancer
|
2010
|
1.39
|
|
48
|
Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study.
|
J Clin Endocrinol Metab
|
2002
|
1.38
|
|
49
|
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
|
J Clin Oncol
|
2009
|
1.36
|
|
50
|
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
|
Nat Biotechnol
|
2008
|
1.24
|
|
51
|
The impact of gross total resection on local control and survival in high-risk neuroblastoma.
|
J Pediatr Surg
|
2004
|
1.20
|
|
52
|
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
|
Blood
|
2002
|
1.18
|
|
53
|
Validation and clinical utility of prostate cancer biomarkers.
|
Nat Rev Clin Oncol
|
2013
|
1.17
|
|
54
|
Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.
|
Biol Blood Marrow Transplant
|
2011
|
1.15
|
|
55
|
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.
|
Biol Blood Marrow Transplant
|
2008
|
1.13
|
|
56
|
Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.
|
Blood
|
2011
|
1.12
|
|
57
|
Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors.
|
Blood
|
2002
|
1.12
|
|
58
|
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
|
J Urol
|
2007
|
1.07
|
|
59
|
Rapid androgen cycling as treatment for patients with prostate cancer.
|
Clin Cancer Res
|
2006
|
1.03
|
|
60
|
Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
|
Br J Haematol
|
2008
|
1.03
|
|
61
|
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.
|
Blood
|
2012
|
1.02
|
|
62
|
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.
|
Blood
|
2011
|
1.02
|
|
63
|
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
|
Cancer Res
|
2003
|
1.02
|
|
64
|
Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2009
|
0.99
|
|
65
|
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
|
Biol Blood Marrow Transplant
|
2007
|
0.99
|
|
66
|
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.
|
J Natl Cancer Inst
|
2010
|
0.98
|
|
67
|
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.
|
Blood
|
2014
|
0.97
|
|
68
|
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2007
|
0.92
|
|
69
|
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
|
Clin Cancer Res
|
2011
|
0.92
|
|
70
|
Organ-derived dendritic cells have differential effects on alloreactive T cells.
|
Blood
|
2008
|
0.90
|
|
71
|
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.89
|
|
72
|
Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study.
|
J Clin Endocrinol Metab
|
2004
|
0.89
|
|
73
|
Lehmann family of ROC curves.
|
Med Decis Making
|
2010
|
0.88
|
|
74
|
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.
|
Cancer
|
2008
|
0.88
|
|
75
|
Prevalence of vitamin D insufficiency in survivors of childhood cancer.
|
Pediatr Blood Cancer
|
2012
|
0.88
|
|
76
|
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
|
Urology
|
2005
|
0.86
|
|
77
|
IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
|
J Immunol
|
2007
|
0.85
|
|
78
|
Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.84
|
|
79
|
Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses.
|
J Immunol
|
2005
|
0.83
|
|
80
|
The use of back-up units to enhance the safety of unrelated donor cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
81
|
Picking the winners in a sea of plenty.
|
Clin Cancer Res
|
2002
|
0.82
|
|
82
|
Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).
|
Biol Blood Marrow Transplant
|
2011
|
0.81
|
|
83
|
DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation.
|
J Immunol
|
2006
|
0.80
|
|
84
|
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.
|
Leuk Res
|
2013
|
0.79
|
|
85
|
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
|
Cancer J
|
2016
|
0.78
|
|
86
|
Factors associated with relapse and survival in Wilms tumor: a multivariate analysis.
|
J Pediatr Surg
|
2012
|
0.77
|
|
87
|
Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner.
|
J Immunol
|
2006
|
0.76
|
|
88
|
Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data.
|
Appl Health Econ Health Policy
|
2010
|
0.76
|
|
89
|
Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy.
|
Cancer
|
2002
|
0.76
|
|
90
|
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
|
Urology
|
2004
|
0.76
|
|
91
|
Response: Sample size and statistical comparisons of GVHD rates in pediatric Niemann-Pick disease patients.
|
Blood
|
2010
|
0.75
|
|
92
|
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
|
Cancer
|
2013
|
0.75
|
|
93
|
Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications.
|
J Immunother
|
2007
|
0.75
|
|
94
|
Inference for the difference in the area under the ROC curve derived from nested binary regression models.
|
Biostatistics
|
2016
|
0.75
|
|
95
|
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial.
|
Urology
|
2003
|
0.75
|